Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.48 |
| ▸ | PPARA | Q07869 | 15/20 | 0.48 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716359 | 0.93 | NPC1 (0.43) | PPARGPPARAPPARDMEN1KMT2A | |
| SCHEMBL6714967 | 0.86 | PPARG (0.65) | PPARGPPARAPPARDMEN1KMT2A | |
| SCHEMBL6716108 | 0.83 | PPARG (0.46) | PPARGPPARAPPARDMEN1KMT2A | |
| SCHEMBL6713322 | 0.83 | PPARG (0.49) | PPARGPPARAPPARDMEN1KMT2A | |
| SCHEMBL6716379 | 0.82 | PPARG (0.67) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6713285 | 0.82 | PPARG (0.59) | PPARGPPARAPPARDMEN1KMT2A | |
| SCHEMBL6715125 | 0.81 | PPARG (0.62) | PPARGPPARAPPARDNPC1RAB9A | |
| SCHEMBL6713214 | 0.81 | PPARG (0.58) | PPARGPPARAPPARDNPC1RAB9A | |
| SCHEMBL6714896 | 0.80 | PPARG (0.60) | PPARGPPARAPPARDNPC1RAB9A | |
| SCHEMBL6713127 | 0.80 | NPC1 (0.52) | PPARGPPARAPPARDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | PPARG 23/4885PPARA 71/4885PPARD 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.